The 2025 AHA/ACC Hypertension Guidelines: Key Updates, Historical Context, and Clinical Implications

Abstract

This review examines the 2025 American Heart Association/American College of Cardiology multisociety hypertension guideline, placing its recommendations in historical context and evaluating the supporting evidence across major clinical populations. The 2025 guideline retains the 2017 blood pressure categories and treatment goal of less than 130/80 mmHg but introduces the race-free PREVENT equations, uses a 7.5% 10-year risk threshold to guide pharmacologic treatment of stage-1 hypertension, and encourages systolic blood pressure below 120 mmHg in selected high-risk patients. Additional updates include single-pill combination therapy for stage-2 hypertension, broader primary aldosteronism screening, routine urine albumin-to-creatinine ratio measurement, removal of race-based drug selection, and cautious incorporation of renal denervation. Recent trials strengthen the evidence for intensive lowering, including in diabetes and older adults. The 2025 guideline advances a risk-based, measurement-dependent approach. The principal challenge is no longer identifying effective treatments but delivering accurate measurement, timely intensification, and sustained follow-up at scale.